PI3K inhibitorFDA-approvedSecond-line
Alpelisib
How it works
Blocks the PI3K enzyme that regulates cell growth and division in cancer cells, preventing growth and causing cell death.
Cancer types
Breast Cancer— PIK3CA-mutated
Efficacy
In clinical trials, around 10-20% of PIK3CA-mutated patients achieved a partial response to alpelisib-based therapy.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Evaluating Treatments for Advanced Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Everolimus After Alpelisib in Hormone Receptor-positive Metastatic Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Evaluating Alpelisib and Fulvestrant for Advanced Breast Cancer in Japan | Breast Cancer | phase-2 | — | Source → |
| Alpelisib and Fulvestrant in Advanced Breast Cancer: Real-World Analysis | Breast Cancer | observational | The median progression-free survival was 5.0 months, and the median overall survival was 20.1 months. | Source → |
| Combining Pyrotinib and Alpelisib May Help Treat HER2+ Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Alpelisib Shows Promise in Advanced Breast Cancer Treatment | Breast Cancer | observational | The median progression-free survival on alpelisib was 5.5 months. | Source → |
| Alpelisib and Endocrine Therapy Show Promise for Advanced Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Alpelisib and Letrozole May Help Some Breast Cancer Patients | Breast Cancer | phase-2 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.